Literature DB >> 22833690

Synthesis and characterization of acetalated dextran polymer and microparticles with ethanol as a degradation product.

Kevin J Kauffman1, Clement Do, Sadhana Sharma, Matthew D Gallovic, Eric M Bachelder, Kristy M Ainslie.   

Abstract

In the field of drug delivery, pH-sensitive polymeric microparticles can be used to release therapeutic payloads slowly in extracellular conditions (pH 7.4) and faster in more acidic areas in vivo, such as sites of inflammation, tumors, or intracellular conditions. Our group currently uses and is further developing the pH-sensitive polymer acetalated dextran (Ac-DEX), which is a biodegradable polymer with highly tunable degradation kinetics. Ac-DEX has displayed enhanced delivery of vaccine and drug components to immune and other cells, making it an extremely desirable polymer for immune applications. Currently, one of the degradation products of Ac-DEX is methanol, which may cause toxicity issues if applied at high concentrations with repeated doses. Therefore, in this manuscript we report the first synthesis and characterization of an Ac-DEX analog which, instead of a methanol degradation product, has a much safer ethanol degradation product. We abbreviate this ethoxy acetal derivatized acetalated dextran polymer as Ace-DEX, with the 'e' to indicate an ethanol degradation product. Like Ac-DEX, Ace-DEX microparticles have tunable degradation rates at pH 5 (intracellular). These rates range from hours to several days and are controlled simply by reaction time. Ace-DEX microparticles also show minimal cytotoxicity compared to commonly used poly(lactic-co-glycolic acid) (PLGA) microparticles when incubated with macrophages. This study aims to enhance the biocompatibility of acetalated dextran-type polymers to allow their use in high volume clinical applications such as multiple dosing and tissue engineering.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22833690     DOI: 10.1021/am3008888

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  20 in total

1.  Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.

Authors:  Naihan Chen; Monica M Johnson; Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2018-02-02       Impact factor: 9.776

2.  Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.

Authors:  Naihan Chen; Matthew D Gallovic; Pamela Tiet; Jenny P-Y Ting; Kristy M Ainslie; Eric M Bachelder
Journal:  J Control Release       Date:  2018-09-24       Impact factor: 9.776

3.  Saquinavir Loaded Acetalated Dextran Microconfetti - a Long Acting Protease Inhibitor Injectable.

Authors:  Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Craig D Sykes; Angela Kashuba; Kristy M Ainslie
Journal:  Pharm Res       Date:  2016-05-06       Impact factor: 4.200

4.  A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.

Authors:  Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Michael A Collier; Rebekah Watkins-Schulz; Ning Cheng; Clément N David; Charles E McGee; Gregory D Sempowski; Ivo Shterev; Karen McKinnon; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

5.  Needle-Free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge.

Authors:  Ky V Hoang; Heather Curry; Michael A Collier; Hassan Borteh; Eric M Bachelder; Larry S Schlesinger; John S Gunn; Kristy M Ainslie
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

6.  Acetalated dextran encapsulated AR-12 as a host-directed therapy to control Salmonella infection.

Authors:  Ky V Hoang; Hassan M Borteh; Murugesan V S Rajaram; Kevin J Peine; Heather Curry; Michael A Collier; Michael L Homsy; Eric M Bachelder; John S Gunn; Larry S Schlesinger; Kristy M Ainslie
Journal:  Int J Pharm       Date:  2014-10-22       Impact factor: 5.875

7.  A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity.

Authors:  Rebekah Watkins-Schulz; Pamela Tiet; Matthew D Gallovic; Robert D Junkins; Cole Batty; Eric M Bachelder; Kristy M Ainslie; Jenny P Y Ting
Journal:  Biomaterials       Date:  2019-03-14       Impact factor: 12.479

8.  Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Authors:  Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-10-15       Impact factor: 4.939

9.  Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine Applications.

Authors:  Kathryn M Moore; Cole J Batty; Rebeca T Stiepel; Christopher J Genito; Eric M Bachelder; Kristy M Ainslie
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-24       Impact factor: 9.229

10.  Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.

Authors:  Elizabeth G Graham-Gurysh; Ananya B Murthy; Kathryn M Moore; Shawn D Hingtgen; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2020-04-23       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.